Corcept Therapeutics Incorporated
CORT
Rang in aandelen
#1723
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Aandeelprijs
$115.39
Marktkapitalisatie
$12.47B
Verandering (1 dag)
2.93%
Verandering (1 jaar)
46.81%
Land
US
Handel Corcept Therapeutics Incorporated (CORT)
Categorie
Healthcare
Aantal uitstaande aandelen voor Corcept Therapeutics Incorporated (CORT)
Aantal uitstaande aandelen per June 2026: 105.38M
Volgens de laatste financiële rapporten en de aandelenkoers van Corcept Therapeutics Incorporated bedraagt het huidige aantal uitstaande aandelen 105.38M. Aan het einde van December 2023 had het bedrijf 103.56M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Corcept Therapeutics Incorporated (CORT) van 2001 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 105.38M | 2.08% |
| 2024 | 103.23M | -0.32% |
| 2023 | 103.56M | -3.02% |
| 2022 | 106.79M | -7.67% |
| 2021 | 115.65M | 0.21% |
| 2020 | 115.41M | 0.93% |
| 2019 | 114.35M | -9.02% |
| 2018 | 125.68M | 10.71% |
| 2017 | 113.53M | 2.68% |
| 2016 | 110.57M | 3.53% |
| 2015 | 106.80M | 5.77% |
| 2014 | 100.98M | 1.16% |
| 2013 | 99.82M | 7.31% |
| 2012 | 93.02M | 11.65% |
| 2011 | 83.31M | 21.91% |
| 2010 | 68.34M | 30.31% |
| 2009 | 52.44M | 12.25% |
| 2008 | 46.72M | 36.41% |
| 2007 | 34.25M | 49.95% |
| 2006 | 22.84M | 1.03% |
| 2005 | 22.61M | 22.60% |
| 2004 | 18.44M | 113.17% |
| 2003 | 8.65M | 28.73% |
| 2002 | 6.72M | 25.00% |
| 2001 | 5.38M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 445.06M | 322.35% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 18.05B | 17,027.57% |
HK
|
